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Murray F! Ducharme, Pharm.D., and Paul Munzenberger, Pharm.D. 
A 40-month-old child was sedated with a fentanyl and midazolam infusion for 
7 days. After the drugs were discontinued he became unresponsive and 
globally aphasic, and had marked thrombocytosis. He was hospitalized for 4 
weeks, during which time his motor and cognitive status slowly improved, 
and had almost returned to baseline at time of discharge. Severe neurologic 
abnormalities have been reported with midazolam and fentanyl, administered 
separately or together, and seem to be a consequence of a withdrawal 
syndrome. Of interest, this patient had a reactive thrombocytosis at the time 
of onset of the withdrawal syndrome, and his decreased platelet count 
coincided with the return to normal cognitive and motor status. Based on this 
experience and other reports, we believe midazolam-fentanyl combination 
should be administered with caution. 
(Pharmacotherapy 1995; 15( 5):665-668) 
Midazolam and fentanyl are commonly given 
in combination for sedation to patients requiring 
surgery or intensive care. This combination is 
synergistic for analgesia and sedation associated 
with anesthesia.’-* It may have induced severe 
neurologic abnormalities in a young child. 
Case Report 
A 40-month-old, 15.4-kg boy was admitted to 
Children’s Hospital of Michigan in January 1992 
for an elective tracheolaryngoplasty. The child 
had normal mental development and no known 
drug allergy. His medical history included 
Pfeiffer syndrome with craniofacial stenosis, and 
recent tracheostomy. Tracheolaryngoplasty was 
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performed successfully on January 8, 1992, in 
what was considered an uneventful procedure. 
The patient was anesthetized during surgery with 
halothane. Other drugs given during surgery 
were gentamicin 40 mg in 500 ml normal saline 
for irrigation, 0.5% lidocaine with epinephrine 
1:200,000, and cefazolin 300 mg intravenously 1 
hour before the end of the procedure. The 
patient was paralyzed with pancuronium 1.5 mg 
intravenously every 10 minutes on the day of 
surgery; the next day this was replaced with 
vecuronium 1.5 mg every hour as needed for 6 
days to allow for healing. 
During this period, sedation and analgesia 
were provided with infusions of fentanyl 1 
pg/kg/hour and midazolam 0.5 pg/kg/minute. 
The midazolam dosage was increased to 2 
pg/kg/minute during the week due to the 
development of tolerance. Between January 10 
and 15, the child experienced several episodes of 
hypotension that required dopamine and 
dobutamine infusions to maintain perfusion. 
The dosages were dopamine 7.5 pg/kg/minute 
between January 10 and 15, and dobutamine 5 
pg/kg/minute from January 14 to 15. Four doses 
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of dexamethasone 5 mg intravenously were also 
ordered between January 15 and 16. During that 
time the midazolam and fentanyl infusion rates 
were decreased by S O % ,  and the child was 
observed closely for 14 hours. The infusion was 
discontinued early on January 17. 
The child's recovery from sedation and 
analgesia was classified as uneventful. He awoke 
apparently normal, and could nod his head and 
answer questions. Although never documented 
by hospital personnel, on that day the boy 
apparently complained to his parents of 
temporary blindness. He was described as being 
agitated between January 16 and 18, and received 
secobarbital 50 mg once and chloral hydrate 225 
mg twice for sedation. The child was seen to 
play with toys on the evening of January 17 and 
was discharged the next morning. 
Once home, the family stated that the boy 
became unresponsive and lay in his bed in a fetal 
position, and was unable to recognize his 
parents. He was readmitted to the hospital the 
same day he was discharged. 
On January 18 and 19  the patient was 
unresponsive, had nonpurposeful movements, 
and  was globally aphasic. Computerized 
tomography of the head, electroencephalogram, 
and  spinal tap were ordered to rule out  a 
subdural hematoma or a cerebral ischemic event 
such as a stroke. The results were unremarkable. 
Laboratory values were normal with the 
exception of thrombocytosis peaking at  
1 ,230,000/mm3 on January 20, which coincided 
with his worse cognitive and motor status. The 
patient received aspirin 80 mg/day to prevent a 
possible thrombotic event while his platelet 
count was over 700,000/mm3. The Division of 
Pharmacology was consulted after a review of the 
literature revealed published cases of neurologic 
abnormalities associated with midazolam and 
fentanyl infusions in children.6 
After limited cognitive and motor improve- 
ment  during the first week, the child was 
transferred to the rehabilitation unit for the next 
month. He was discharged on February 11. 
Four weeks after midazolam and fentanyl were 
discontinued, his motor and neurologic status 
were continuously improving and had returned 
to baseline except for speech that was still 
limited. 
Discussion 
Fentanyl and midazolam are frequently 
administered in combination. Their popularity 
for induction of anesthesia is based at least in 
part on literature reports of synergism.2% Three 
groups of 60 women had induction of anesthesia 
with fentanyl, midazolam, or a combination of 
the two. The group receiving combination 
therapy required 75% less fentanyl and 77% less 
midazolam than the other two groups.' Similar 
results were obtained with a combination of 
alfentanil plus midazolam; when given together, 
the doses could be decreased by 78% and 68%, 
respectively. 
Unfortunately, not only desirable effects are 
enhanced when these drugs are administered 
together. Moderate to severe decreases in blood 
pressure, cardiac index, and stroke index 
occurred in patients receiving the combination 
for coronary artery bypass graft, in contrast to a 
control group receiving only high-dose f en tan~ l .~  
Decreases in heart rate and blood pressure were 
also reported when fentanyl was combined with 
diazepam for anesthesia inquction in a study of 
72 patients.* The frequency of apnea and 
hypoxemia was also increased when midazolam 
and fentanyl were combined, compared with each 
drug alone.' 
Known side effects of midazolam and fentanyl 
include respiratory depression, hallucinations, 
and impaired memory." Of importance to this 
case are a number of reports describing 
unexpected events associated with the agents. 
Tolerance, for example, was reported by several 
investigators. 11-14 This phenomenon led to 
increased dosages of the drugs, dependence on 
mechanical ventilation, and neurologic side 
effects. Tolerance with drug accumulation was 
also reported with fentanyl,15 midazolam,16x l7 
midazolam and morphine,18 and midazolam and 
fentanyl.6 These reports described possible 
withdrawal syndromes consisting of neurologic 
abnormalities precipitated by abrupt cessation of 
the drugs. 
The withdrawal syndromes were treated in 
some cases by restarting and slowly tapering the 
offending agents. For example, after a 7-day 
course of midazolam and morphine,  the 
syndrome was controlled by giving and tapering 
diazepam over 7 days." One group tapered 
diazepam over 3 weeks after 6 days of midazolam 
infusion.16 Others, however, did not taper the 
dosages of midazolam and fentanyl, and fentanyl 
alone,6, l5 and the withdrawal syndrome lasted 
from 1-6 weeks in  the four patients they 
reported. This length of time compares well with 
that in our patient, which was at least 4 weeks. 
In addition to neurologic side effects, our 
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patient experienced a hypotensive episode 
necessitating a dopamine drip during the 
midazolam-fentanyl infusions, with a marked 
elevation of his platelet count  after dis- 
continuation of these two drugs. Although 
hypotension was reported during midazolam 
infusion in six babies age 12-36 hours,” we are 
unaware of any report  of thrombocytosis 
associated with either agent, and the relationship 
in our patient is unclear. On the other hand, 
reactive thrombocytosis was reported after acute 
withdrawal from alcohol” and myelosuppressive 
drugs,” and was observed in  patients with 
chronic or acute inflammatory disorders.22 
The thrombocytosis in this child could well 
have been a reactive manifestation of a possible 
fentanyl and midazolam withdrawal syndrome. 
Furthermore,  a relationship between the 
deterioration in motor and cognitive status and 
this reactive thrombocytosis was seen when 
comparing indexes of cognitive and motor status 
observed daily by his mother with the patient’s 
platelet count. Cognitive status was defined as 
poor (unable to talk), vocalize without meaning, 
limited vocalization, or normal (based on  
mother’s assessment). Motor status was defined 
as poor (move without purpose), limited (move 
with purpose but not normal), or normal (based 
on mother’s assessment). Of interest, available 
data suggest that the return to a normal platelet 
count coincided with a return to normal motor 
and cognitive status. These observations are in 
agreement with a possible reactive thrombo- 
cytosis induced by a withdrawal syndrome. 
Midazolam, because of its relatively short half- 
life of 1-4 hours,” is a widely used benzodiazepine 
for induction of anesthesia. However, with respect 
to tolerance and development of a withdrawal 
syndrome, several studies and expert commentaries 
suggest that the shorter a benzodiazepine’s half- 
life, the greater the possibility of these untoward 
reactions when the drug is discontinued 
r a ~ i d l y . ~ ~ - ~ ~  One suggested method for treating 
benzodiazepine-induced withdrawal syndrome is 
to coadminister a longer-acting opiate and 
benzodiazepine, such as morphine and diazepam, 
during the early phase and slowly taper the 
dosage. 16, l8 
Our patient may have benefited from such an 
approach. A return to a normal cognitive and 
motor status would have confirmed our suspicion 
of a withdrawal syndrome. Unfortunately, it was 
not possible for us to readminister these drugs, as 
the family was extremely sensitive to any 
pharmacologic treatment. 
Neither the intensive care uni t  (ICU) 
syndrome nor a steroid psychosis could explain 
this patient’s disorder. The ICU syndrome 
consists of psychologic reactions ranging from 
fear to delirium, usually appears during the ICU 
stay, and disappears within 48  hours  after 
discharge from the unit.26 Our patient’s clinical 
picture, very much consistent with a stroke, 
could never really substantiate a steroid 
psychosis, which is also usually related to 
dosage.27 Prolonged neuromuscular blockade has 
been reported after vecuronium administration.2c30 
In these patients, however, neuromuscular 
function continued to be suppressed for days 
after the drug was discontinued. In contrast, our 
patient’s neuromuscular function returned to 
normal for 24 hours before worsening. 
This case report suggests that a midazolam- 
fentanyl combination may not  have been 
appropriate for long-term analgesia and sedation 
in this child. The abrupt discontinuation of the 
drugs was possibly associated with a severe 
withdrawal syndrome. A reactive thrombocytosis 
paralleled the severity of the decline in motor 
and cognitive status. Based on our experience 
and other published case reports, this drug 
combination should be given with extreme 
caution. When it is to be administered for a long 
period of time, substituting the either drug for 
longer-acting agents (e.g., diazepam, morphine) 
may be necessary. The dosage can then be 
tapered slowly over 118 to 3 weeks“j to avoid a 
withdrawal syndrome. 
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